Treatment-Related Mortality From Infectious Complications in an Acute Leukemia Clinic

Background

The main causes of mortality in patients with acute leukemia are the infectious complications. The author wanted to know the induction-related mortality and treatment-related mortality in the acute leukemia patients at the Instituto Nacional de Cancerologia (INCan), Mexico. Also the author is interested in finding out the micro-organism and the main site of infection to make some changes in the management of patients in these clinics. Primary objective was induction chemotherapy-related mortality and treatment-related mortality. Secondary objective was to determine the site of infection, micro-organism, type of chemotherapy related with more mortality and relapse mortality.

Methods

This was a retrospective case-series analysis of all patients who were admitted to the INCan Acute Leukemia Clinic between January 2012 and December 2015 with febrile neutropenic complications. We reviewed the case histories of all patients, including those with acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), acute biphenotypic leukemia and acute promyelocytic leukemia, regardless of disease status (newly diagnosed or relapsed) at the time of clinic attendance. Patients who died as the result of an infectious complication during the analysis window were identified, and their demographics, disease characteristics, treatment history (chemotherapy within 45 days of date of death) and details of the infectious complication resulting in death were collected.

Results

Of the 313 patients studied during that time period, 84 (27%) died as a result of infectious complications. Lung infections were the most common, accounting for 67% of all deaths from infectious complications. Escherichia coli producing extended-spectrum beta-lactamases was the most frequently isolated infectious organism (12 patients; 14%). The majority of deaths occurred during either induction therapy (27 patients; 32%) or treatment for a first relapse (25 patients; 30%). Hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD) was the chemotherapy regimen most commonly received within 45 days prior to death (17 patients; 20%).

Conclusions

Our findings suggest a need for long-term management and supportive care to prevent infectious complication-associated fatalities during both initial chemotherapy and subsequent disease relapse in patients with acute leukemia. The use of prophylaxis will help patients to prevent complications.

Leptospirosis in an asplenic patient -case report

Background

The presentation of clinical leptospirosis has been historically associated with animal workers, slaughterhouse workers and medical veterinarians. This association has shifted to be related to flooding events and outdoor activities; few cases are related to high-risk factors found in immunosuppressed patients. Scarcely a handful of cases have serological evidence of immune response against Leptospira serovar Bratislava representing serogroup Australis, a serovar associated with poor reproductive performance in swine and horses, and recently with cats.

Case presentation

Herein, we describe a rare clinical presentation of disseminated Leptospira infection in an immunosuppressed 65-year-old woman. She was admitted to the emergency room with fever, bacteraemia, bilateral uveitis and pulmonary involvement. The patient denied outdoor activities; she only had wide exposure to faeces and urine from cats living in her home. Her medical history included idiopathic thrombocytopenic purpura (ITP) diagnosed at the age of 18. She did not respond to medical treatment, and a splenectomy was performed. At age 60, she was diagnosed with Chronic Myeloid Leukemia (CML), and was treated with a tyrosine kinase inhibitor (TKI) –Imatinib. The patient voluntarily discontinued the treatment for the last 6 months. After extensive workup, no microorganisms were identified by the commonly used stains in microbiology. The diagnosis was performed through dark-field microscopy, microagglutination test (MAT), Leptospira genus-specific PCR, the IS1500 PCR for identification of pathogenic species, and 16S based sequencing for the genus identification.

Conclusion

Immunosuppressed patients may acquire uncommon infections from ubiquitous microorganisms. In this case, serology evidence of exposure to Leptospira serovar Bratislava by MAT and the presence of the Leptospira genus were identified. It should be on mind for the diagnosis in otherwise healthy patients, and thoroughly search on splenectomised patients exposed to animals. Additionally, this report highlights the usefulness of PCR for diagnosis of this potentially life-threatening illness.

[National guidelines of diagnosis and treatment of the non-Hodgkin lymphoma]

Non-Hodgkin lymphoma comprises a heterogeneous group of haematological malignancies, classified according to their clinic, anatomic-pathological features and, lately, to their molecular biomarkers. Despite the therapeutic advances, nearly half of the patients will die because of this disease. The new diagnostic tools have been the cornerstone to design recent therapy targets, which must be included in the current treatment guidelines of this sort of neoplasms by means of clinical trials and evidence-based medicine. In the face of poor diagnoses devices in most of the Mexican hospitals, we recommend the present diagnose stratification, and treatment guidelines for non-Hodgkin lymphoma, based on evidence. They include the latest and most innovative therapeutic approaches, as well as specific recommendations for hospitals with limited framework and therapy resources.

Zygomycosis in two hematologic cases

Zygomycosis are invasive mould infections, rarely diagnosed in hematologic patients. Most of the cases published are in patients with prolonged neutropenia, along with other risk factors such as the use of prior broad-spectrum antibiotics (including new antifungal agents, such as voriconazole), diabetes mellitus (with or without ketoacidosis), malnutrition, iron overload (with or without the use of deferoxamine). These infections have poor prognosis due to the involvement of vital anatomic structures and late diagnosis. Until recent years, the treatment was based on high doses of amphotericin B plus surgical debridement. Here we present two patients with hematologic diseases (one with leukemia, the second with aplastic anemia) with an impaired immune system and the diagnosis of zygomycosis. The survival of one of them was mainly due to early diagnosis and surgical debridement; unfortunately the second was misdiagnosed as an extensive ecchymosis due to thrombocytopenia and died with CNS involvement.

Whole-body (18)F-FDG PET/CT in primary non-Hodgkin's lymphoma of the thyroid associated with Hashimoto's thyroiditis and bilateral kidney infiltration

An 82-year-old female patient with hypothyroidism and Hashimoto's thyroiditis noted three years ago to have a small asymmetric goiter (left > right). Nevertheless, a rapid growth of the thyroid over 3-6 months caused dysphagia and shortness of breath. Ultrasound and a thyroid gammagram showed an image consistent with multinodular goiter with a hyperfunctioning nodule in the right lobe. Due to the history of Hashimoto's thyroiditis and a rapid increase in size of the thyroid gland, diagnoses of thyroid lymphoma and anaplastic thyroid cancer were considered. Thyroidectomy was attempted at an outside facility to relieve compressive symptoms. Fine needle aspiration was insufficient for diagnosis, and the product of thyroidectomy confirmed the diagnosis of diffuse large B-cell lymphoma. A positron emission tomography/computed tomography scan was performed in our institution for staging, revealing nodal and extranodal metastasis. Chemotherapy using cyclophosphamide, vincristine and dexamethasone (COP modified) led to a dramatic response of the tumor and a complete resolution of compressive symptoms.

The relevance of performing a bone marrow aspirate and biopsy in breast cancer patients with suspected bone marrow metastasis

18605

Background: Patients with breast cancer often presents hematological abnormalities during the disease evolution, frequently it is difficult to define if these are due to bone marrow infiltartion or are due to drug toxicity or a new hematological disorder. To determine the proportion of patients with bone marrow metastasis we reviewed the bone marrow aspirates and biopsies of patients with histological proven breast cancer and an abnormal peripheral blood count referred to the Hematology Department. Methods: We reviewed the medical records of 88 patients referred to our Department from april 1998 to april 2005 with breast cancer and with bone marrow smears and biopsies. The BM smears were interpreted blindly by one of us. The BM biopsies were reviewed independently by a hematopatologist. A statistician analysed the data and estimated frequencies and rates, survival analysis was estimated by means of the Kaplan-Meier method. Results: Median age 47.7 years (range 28–80), clinical stage at diagnosis was: II, 19 (21.1%); IIIA, 19 (21.1%); IIIB, 16 (17.8%); IV, 34 (40%). The hematological abnormality that triggered the referral was: Thrombocytopenia, 61 (67.8%); anemia, 53 (58.9%); leucopenia, 47 (53.4%); thrombocytopenia and anemia, 39 (43.3%). The median time from the initial diagnosis to the BM biopsy was 12.8 months (range 1 to 176.7). Regarding the BM aspirates interpretatrion: 17 were not evaluable, 53 were negative for infiltration, 17 were positive for carcinoma and 1 with plasma cell infiltration (this patients had concurrent Breast cancer and myeloma). BM biopsies: 19 were not evaluable, 48 were negative, 20 positive and 1 with myeloma. The sensitivity of the BM aspirates was 75% (12/16) and the specificity 95% (41/43). The median survival of the patients with BM metastais was 109 months, and 104 of the patients without BM metastasis (p = 0.9767) Conclusions: Most of the patients with hematological abnormalities do not have BM infiltration, bone marrow biopsies have more sensitivity than aspirates. The presence of BM metastasis does not necessarily predicts a short survival period.

No significant financial relationships to disclose.

Primary lymphoma of bone

Primary lymphoma of bone (PLB) is a rare clinical-pathological entity representing less than 1% of all lymphomas. This work was aimed to review the presentation characteristics of PLB at the Instituto Nacional de Cancerología including its management and evolution.

MATERIAL AND METHODS

Thirty cases of lymphoma of bone were diagnosed between 1972 and 1999 from a database including 577 patients with lymphoma. Among them, only 8 patients (1.36% of the total lymphomas) met the criteria set out to be diagnosed as primary lymphoma of bone, stage IE. In all patients, diagnosis was histopathologically made through open biopsy, and they were classified in accordance with the former criteria of the Working Formulation (WF). This review applied the current criteria of the World Health Organization (WHO).

RESULTS

Three women and five men with a mean age of 40 years (range 20-65) were identified. Mean physical performance (Karnofsky) was 80%. Six patients presented clinically evident disease of the affected region. The most frequent symptom was pain at the site of the lesion in 3 patients, being the cardinal symptom in 1 patient. Histological diagnosis was diffuse large cell lymphoma, and B immunophenotype was confirmed in 5 patients. Five patients received sequential chemotherapy and radiotherapy; 1 patient received chemotherapy; and 2 patients received exclusive radiotherapy. The chemotherapy regimes were based on anthracyclines. Five patients presented complete response and 3 patients showed progressive disease. One patient showing complete response relapse 16 years after the treatment. The mean follow-up in this series was 60 months (range 3-190 months). Tumor localization and functional condition of the patient were the best prognostic factors. Surgery was not therapeutic in any case.

CONCLUSIONS

PLB still remains a rare clinical-pathological entity, and represented 1.3% of total lymphomas in this series. Sequential anthracycline-based chemotherapy and radiotherapy are the most important therapeutic choices. Functional condition of patients at diagnosis and tumor localization were the most accurate prognostic factors.